Cisplatin versus carboplatin in advanced ovarian cancer: An economic analysis

D. Alberts, E. Hannigan, R. Canetta, R. O'Toole, V. Malviya, E. Surwit, W. Nahhas, C. Jolles, J. Jacobs, S. Pashko

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

By comparing treatment efficacy and cost, the authors evaluate the use of cisplatin and carboplatin for stage III or IV ovarian cancer. Differences in toxicity-related care, including hospitalizations, are investigated to ascertain the advisability of substituting one drug for another.

Original languageEnglish (US)
Pages (from-to)692+697-700+705-706
JournalP and T
Volume19
Issue number7
StatePublished - Jan 1 1994

ASJC Scopus subject areas

  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Cisplatin versus carboplatin in advanced ovarian cancer: An economic analysis'. Together they form a unique fingerprint.

  • Cite this

    Alberts, D., Hannigan, E., Canetta, R., O'Toole, R., Malviya, V., Surwit, E., Nahhas, W., Jolles, C., Jacobs, J., & Pashko, S. (1994). Cisplatin versus carboplatin in advanced ovarian cancer: An economic analysis. P and T, 19(7), 692+697-700+705-706.